Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather
Briefly

Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather
"It's been a fantastic 2026 for most dividend stocks so far this year, but most dividend-payers took a break last week. The Schwab U.S. Dividend Equity ETF was flat while the Consumer Staples SPDR fell 1.8%. With the stock market opening in about 90 minutes for the week, let's take a look back at which dividend stocks saw the biggest movements last week. Broad Market Snapshot Dividend Stock Performance: Week of Feb 17-20, 2026"
"Crown Castle was the week's most talked-about dividend stock following the company's February 4th earnings report. CEO Christian Hillabrant confirmed the company had terminated its agreement with DISH Wireless following a default on payment obligations. Crown Castle is now seeking to recover over $3.5 billion in unpaid amounts. That is not a rounding error. That is a structural hole in the revenue model of a company that owns over 40,000 cell towers across the United States."
"Barclays analyst Brendan Lynch cut his price target to $91 from $101, maintaining an Equal Weight rating, while other analysts including those at Wells Fargo and Jefferies also reduced their targets. The consensus average sits near $100, but the stock has been trading well below that level. CCI pays a quarterly dividend of $1.0625 per share, already reduced from the prior rate of $1.565 per quarter that was cut in early 2025."
The Schwab U.S. Dividend Equity ETF was flat while the Consumer Staples SPDR fell 1.8% last week. Crown Castle terminated its agreement with DISH Wireless after a payment default and is seeking over $3.5 billion in unpaid amounts. Analysts cut price targets and the company faces tenant concentration risk after a dividend cut from $1.565 to $1.0625 per quarter in early 2025, with management warning of a potential trough year and an expected net loss of $780 million in 2026. AbbVie dropped nearly 3% despite FDA approval of VENCLEXTA plus acalabrutinib for untreated CLL.
Read at 24/7 Wall St.
Unable to calculate read time
[
|
]